Rhythm Pharmaceuticals, Inc.

NasdaqGM:RYTM Stok Raporu

Piyasa değeri: US$6.2b

Rhythm Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Rhythm Pharmaceuticals CEO'su David Meeker, Jul2020 tarihinde atandı, in görev süresi 5.83 yıldır. in toplam yıllık tazminatı $ 17.54M olup, şirket hissesi ve opsiyonları dahil olmak üzere 4.6% maaş ve 95.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.35% ine doğrudan sahiptir ve bu hisseler $ 21.66M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.5 yıl ve 6.9 yıldır.

Anahtar bilgiler

David Meeker

İcra Kurulu Başkanı

US$17.5m

Toplam tazminat

CEO maaş yüzdesi4.60%
CEO görev süresi5.8yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi5.5yrs
Yönetim Kurulu ortalama görev süresi6.9yrs

Son yönetim güncellemeleri

Recent updates

Anlatı Güncellemesi • May 04

RYTM: Hypothalamic Obesity Expansion Will Drive Next Phase Of Upside

Rhythm Pharmaceuticals' consolidated analyst price target has been adjusted slightly higher by a few dollars to $137.67, as analysts update their models around recent EMANATE trial outcomes, hypothalamic obesity launch expectations, and evolving views on next generation MC4R agonist opportunities. Analyst Commentary Recent research updates show a mix of optimism and caution around Rhythm Pharmaceuticals, with several firms adjusting price targets both higher and lower as they factor in EMANATE outcomes, hypothalamic obesity indications, and next generation MC4R agonist programs.
Anlatı Güncellemesi • Apr 19

RYTM: Hypothalamic Obesity Approval Will Drive Next Phase Of Upside

Analysts have nudged their blended price target for Rhythm Pharmaceuticals higher by $0.40 to $137.67, reflecting updated assumptions around revenue growth, profitability, discount rates, and future P/E multiples following recent research updates on Phase 3 trial outcomes and the commercial outlook for Imcivree and hypothalamic obesity. Analyst Commentary Recent research updates present a mixed but generally constructive picture, with several firms adjusting price targets following the EMANATE trial results and evolving expectations for Imcivree and hypothalamic obesity.
Anlatı Güncellemesi • Apr 04

RYTM: Hypothalamic Obesity Expansion Will Drive Next Upside Phase

Rhythm Pharmaceuticals' fair value estimate has moved higher to $137.27 from $135.53, as analysts factor in recent price target revisions that balance EMANATE trial setbacks with continued focus on Imcivree commercial execution and next generation MC4R agonists. Analyst Commentary Street research around Rhythm Pharmaceuticals has shifted meaningfully following the EMANATE readout, with price targets adjusted both higher and lower as analysts weigh clinical risk against the commercial rollout of Imcivree and the potential of next generation MC4R agonists.
Anlatı Güncellemesi • Mar 20

RYTM: Hypothalamic Obesity Approval And Launch Preparations Will Drive Next Upside Phase

The updated analyst model trims the blended price target for Rhythm Pharmaceuticals by about $4 to $135.53 as analysts factor in slightly lower revenue growth and margin assumptions, along with a higher projected future P/E multiple following recent EMANATE trial results and ongoing focus on Imcivree and hypothalamic obesity. Analyst Commentary Recent Street research around Rhythm Pharmaceuticals reflects a mixed but engaged view, with several firms adjusting price targets after EMANATE and other trial updates, as well as ongoing focus on Imcivree and hypothalamic obesity.
Anlatı Güncellemesi • Mar 06

RYTM: Hypothalamic Obesity Launch And Upcoming Data Readouts Will Drive Next Upside Phase

Analysts trimmed their blended price target for Rhythm Pharmaceuticals by a few dollars, reflecting slightly more conservative long-term revenue and margin assumptions, even as they continue to highlight the potential of IMCIVREE and the hypothalamic obesity opportunity. Analyst Commentary Recent Street research around Rhythm Pharmaceuticals shows a mix of enthusiasm about the IMCIVREE franchise and the hypothalamic obesity opportunity, along with some recalibration of long-term expectations that feeds into updated price targets.
Yeni Anlatı • Feb 21

Rare Obesity Leadership: Can Setmelanotide Scale Beyond the Clinic?

Rhythm Pharmaceuticals enters late February 2026 as the leader in "rare disease obesity," a niche that has remained remarkably insulated from the broader GLP-1 price wars. The company’s core asset, Setmelanotide , has seen rapid uptake in patients with Bardet-Biedl syndrome (BBS) and POMC deficiency, where traditional weight-loss drugs often fail.
Anlatı Güncellemesi • Feb 18

RYTM: Stable Franchise Trends Will Support Next Phase Of Upside

Analysts have lifted their price target on Rhythm Pharmaceuticals to $145 from $140, citing slightly stronger than expected preannounced Q4 Imcivree revenue of about $57M and what they see as stable growth trends for the existing franchise. Analyst Commentary Recent commentary centers on how the preannounced Q4 Imcivree revenue of about US$57M feeds into expectations for Rhythm Pharmaceuticals' execution and valuation.
Anlatı Güncellemesi • Feb 04

RYTM: March Review Decision Will Drive Next Phase Of Upside

Analysts lifted their price target on Rhythm Pharmaceuticals to US$145 from US$140, citing Q4 Imcivree revenues of about US$57 million coming in slightly ahead of expectations and their view that growth in the existing franchise remains stable. Analyst Commentary Recent commentary around Rhythm Pharmaceuticals focuses on how the latest Imcivree revenue update might influence expectations for growth, execution, and valuation.
Anlatı Güncellemesi • Jan 21

RYTM: March Hypothalamic Obesity Decision Will Drive Next Phase Of Upside

Narrative Update Overview Analysts have inched their fair value estimate for Rhythm Pharmaceuticals higher to about $140 from $139, reflecting slightly higher Street price targets and expectations for steady Imcivree demand after a Q4 revenue preannouncement of roughly $57 million. The update also takes into account more cautious views on how much near term upside is left around upcoming label and trial milestones.
Anlatı Güncellemesi • Jan 06

RYTM: March Obesity Decision And Prader Willi Data Will Shape Upside

Analysts have nudged their fair value estimate for Rhythm Pharmaceuticals higher to about US$139 per share from roughly US$138, reflecting recent price target increases from several firms, along with views that upcoming label expansion and clinical readouts are already largely reflected in the current share price. Analyst Commentary Recent Street research on Rhythm Pharmaceuticals shows a mix of enthusiasm around the commercial trajectory and upcoming label events, alongside some caution on how much of that story is already reflected in the share price.
Anlatı Güncellemesi • Dec 21

RYTM: March FDA Obesity Decision Will Drive Next Phase Of Upside

Analysts have modestly lifted their fair value estimate for Rhythm Pharmaceuticals to approximately $138 from about $127, reflecting slightly higher long term revenue growth expectations and confidence in upcoming hypothalamic obesity label expansion, despite a recent downgrade on valuation concerns. Analyst Commentary Bullish analysts highlight that Rhythm's strong clinical execution in hypothalamic obesity and Bardet Biedl syndrome, along with robust year to date share performance, support a higher long term revenue trajectory and justify incremental price target increases.
Seeking Alpha • Dec 11

Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster

Summary Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show early efficacy in BMI and hyperphagia reduction, though limited by small sample size and responder heterogeneity. RYTM's HO sNDA PDUFA was delayed to March 2026 for additional FDA analysis, but I remain optimistic on approval with some risk to pediatric labeling. IMCIVREE's current indications provide a revenue floor, while upside hinges on HO approval, PWS data de-risking, and successful oral franchise transition. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Dec 07

RYTM: March FDA Obesity Decision Will Drive Next Phase Of Share Upside

Analysts have edged their average price target for Rhythm Pharmaceuticals slightly higher to about $127 from roughly $126, reflecting confidence that strong Imcivree and bivamelagon data, along with anticipated hypothalamic obesity label expansion, can support continued growth. However, recent gains and a limited near term catalyst slate are tempering enthusiasm.
Anlatı Güncellemesi • Nov 23

RYTM: December FDA Decision Will Drive Next Phase Of Share Upside

Rhythm Pharmaceuticals' analyst price target increased from $121.43 to $126.31, as analysts cite ongoing clinical progress and upcoming regulatory milestones that support further upside for the company’s shares. Analyst Commentary Analysts have recently weighed in on Rhythm Pharmaceuticals, offering both optimistic and cautionary perspectives based on the company's performance, upcoming catalysts, and valuation.
Analiz Makalesi • Nov 07

The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

It's been a sad week for Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ), who've watched their investment drop 12% to...
Anlatı Güncellemesi • Nov 05

RYTM: Upcoming FDA Decision Will Drive Next Phase of Upside Momentum

Analysts have raised their price target for Rhythm Pharmaceuticals from $117.57 to $121.43 per share, citing improved profit margin projections and increased optimism about upcoming label expansions for setmelanotide. Analyst Commentary Recent updates from Street research provide a balanced view on Rhythm Pharmaceuticals, with both bullish and bearish perspectives influencing the company's outlook and valuation.
Anlatı Güncellemesi • Oct 22

Analysts Boost Rhythm Pharmaceuticals Outlook Amid Setmelanotide Progress and Revised Valuation Metrics

The analyst price target for Rhythm Pharmaceuticals was revised upward by $7 to reflect increased optimism from analysts about the company's potential label expansion and expected regulatory progress for setmelanotide in hypothalamic obesity. Analyst Commentary Recent updates from Street research indicate a positive reassessment of Rhythm Pharmaceuticals' prospects, particularly surrounding potential regulatory approval and expanding commercial opportunities for setmelanotide in hypothalamic obesity.
Anlatı Güncellemesi • Oct 08

Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines

Rhythm Pharmaceuticals' analyst price target has increased from $114.86 to $118.36, as analysts cite encouraging clinical data and optimism about setmelanotide's approval prospects in hypothalamic obesity. These factors are driving the revised valuation.
Anlatı Güncellemesi • Sep 24

Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines

The consensus price target for Rhythm Pharmaceuticals was raised to $114.86 as bullish analyst sentiment strengthened on strong Phase 2 obesity trial results, robust Imcivree sales, and optimistic expectations for regulatory milestones and long-term franchise durability. Analyst Commentary Bullish analysts highlight strong Phase 2 trial results for bivamelagon in hypothalamic obesity, demonstrating significant placebo-adjusted BMI reduction at multiple doses and exceeding expectations for efficacy over 14 weeks.
Anlatı Güncellemesi • Aug 07

Rising Genetic Diagnosis Will Expand Rare Disease Treatment Pipelines

A lower future P/E indicates improved earnings expectations, while a higher discount rate suggests increased perceived risk, yet analysts have still raised Rhythm Pharmaceuticals’ fair value to $110.71 per share. What's in the News Rhythm Pharmaceuticals presented new clinical data on bivamelagon (oral MC4R agonist) and setmelanotide (lead asset) in patients with acquired hypothalamic obesity at ENDO 2025; setmelanotide remains FDA approved for syndromic monogenic obesity due to defined genetic deficiencies.
Analiz Makalesi • Jul 10

Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33%

Rhythm Pharmaceuticals, Inc. ( NASDAQ:RYTM ) shares have continued their recent momentum with a 33% gain in the last...
Analiz Makalesi • Jun 25

Rhythm Pharmaceuticals (NASDAQ:RYTM) Has Debt But No Earnings; Should You Worry?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
User avatar
Yeni Anlatı • May 26

Label Expansion And Global Healthcare Will Widen Future Market Opportunities

Label expansion and global commercialization of IMCIVREE are set to drive substantial revenue growth and broaden market reach.
Seeking Alpha • Apr 08

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Summary Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmelanotide to the U.S. and EU, for the treatment of patients with acquired hypothalamic obesity, expected in Q3 of 2025. Company pushing forward with oral MC4R-specific agonist to treat patients with acquired hypothalamic obesity known as bivamelagon; Data from a phase 1/2 study, using bivamelagon for the treatment of patients with acquired hypothalamic obesity, expected in 2nd half of 2025. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Summary Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on Rhythm's robust clinical progress and strategic positioning in the rare genetic obesity market. Rating justification is based on solid revenues, innovative product pipeline, and potential market expansion. Conclusion emphasizes Rhythm's growth potential and recommends it as a compelling speculative investment opportunity. Read the full article on Seeking Alpha
Seeking Alpha • Dec 06

Rhythm Pharmaceuticals: A Key Year Ahead

Summary Rhythm Pharmaceuticals, Inc.'s main asset, imcivree, targets rare genetic obesity disorders; key milestones in 2025 could significantly impact the stock. Positive Phase 3 data and expanded indications for imcivree, including Hypothalamic Obesity, are crucial for future growth. Analysts are optimistic, with multiple Buy ratings and price targets between $65-$80; however, insiders have sold some shares recently. An updated analysis around Rhythm Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Sep 22

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Summary IMCIVREE is FDA-approved for obesity due to genetic mutations and aims to expand its label to include children as young as 2 years old. Rhythm is also exploring IMCIVREE for hypothalamic obesity in a phase 3 study, with data expected in the 1st half of 2025. Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months. RM-718 and LB54640 are two other drugs being developed to treat patients with hypothalamic obesity; Both of which are able to achieve function without hyperpigmentation. Read the full article on Seeking Alpha
Seeking Alpha • Aug 29

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Summary Rhythm Pharmaceuticals' Q2 revenue rose to $29.1 million, driven by global sales of Imcivree, its treatment for rare genetic obesity disorders. The company's cash and investments totaled $319 million by June 30, 2024, ensuring a cash runway into 2026, according to Rhythm's projections. Imcivree is currently undergoing a Phase 3 trial for hypothalamic obesity, with results expected in 1H 2025, crucial for its potential blockbuster status. RYTM stock is a speculative "buy" based on the potential of Imcivree in treating hypothalamic obesity, though there are significant risks if the trial fails. Read the full article on Seeking Alpha
Seeking Alpha • Jun 12

Rhythm: Navigating Imcivree's Potential In Rare Obesity Treatments (Rating Upgrade)

Summary Rhythm Pharmaceuticals' stock has appreciated 68% since the last sell recommendation, outperforming market returns. Imcivree shows promising Phase 2 results in treating hypothalamic obesity, potentially doubling its market if its Phase 3 trial proves successful. The company's financial health appears stable, with a sufficient cash runway extended by recent funding. The Phase 3 trial for Imcivree in heterozygous mutations aims to broaden the addressable population to exceed 50,000. I now hold a more balanced view of RYTM stock, acknowledging its strategic expansions but cautious of its high valuation and ongoing risks. Read the full article on Seeking Alpha
Seeking Alpha • Feb 23

Rhythm Pharmaceuticals: Action Too Specific

Summary Rhythm Pharmaceuticals focuses on treating obesity caused by genetic mutations, but the market size for these mutations is too small to justify the company's valuation. Novo Nordisk's Ozempic also targets the same patient groups, making Rhythm's product less appealing. IMCIVREE, Rhythm's main product, shows good results in clinical trials, but again the action is too specific. Outstanding dilution from options too down the line. Not for us. Read the full article on Seeking Alpha

CEO Tazminat Analizi

David Meeker'un ücretlendirmesi Rhythm Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$208m

Dec 31 2025US$18mUS$808k

-US$202m

Sep 30 2025n/an/a

-US$198m

Jun 30 2025n/an/a

-US$188m

Mar 31 2025n/an/a

-US$174m

Dec 31 2024US$15mUS$740k

-US$265m

Sep 30 2024n/an/a

-US$262m

Jun 30 2024n/an/a

-US$261m

Mar 31 2024n/an/a

-US$274m

Dec 31 2023US$7mUS$705k

-US$185m

Sep 30 2023n/an/a

-US$186m

Jun 30 2023n/an/a

-US$182m

Mar 31 2023n/an/a

-US$181m

Dec 31 2022US$3mUS$652k

-US$181m

Sep 30 2022n/an/a

-US$181m

Jun 30 2022n/an/a

-US$176m

Mar 31 2022n/an/a

-US$166m

Dec 31 2021US$6mUS$630k

-US$70m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$15mUS$262k

-US$134m

Sep 30 2020n/an/a

-US$132m

Jun 30 2020n/an/a

-US$134m

Mar 31 2020n/an/a

-US$146m

Dec 31 2019US$287kn/a

-US$141m

Tazminat ve Piyasa: David 'nin toplam tazminatı ($USD 17.54M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 8.43M ).

Tazminat ve Kazançlar: David şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

David Meeker (71 yo)

5.8yrs
Görev süresi
US$17,544,525
Tazminat

Dr. David P. Meeker, MD, is Member of Advisory Board of Mitotherapeutix, LLC. Dr. Meeker had been Independent Non-Executive Director of Pharvaris N.V. (formerly known as Pharvaris B.V.) since January 1, 20...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
David Meeker
Chairman5.8yrsUS$17.54m0.35%
$ 21.7m
Hunter Smith
CFO & Treasurer8.8yrsUS$6.23m0.17%
$ 10.6m
Alastair Garfield
Chief Scientific Officer1.8yrsUS$4.43m0.011%
$ 703.8k
Yann Mazabraud
Executive VP & Head of International5.6yrsUS$6.12m0.096%
$ 6.0m
Jennifer Lee
Executive VP & Head of North America5.5yrsUS$5.60m0.028%
$ 1.7m
Christopher German
Corporate Controller & Principal Accounting Officer3.2yrsVeri yok0.0062%
$ 385.8k
Joseph Shulman
Chief Technical Officer5.8yrsUS$3.41m0.028%
$ 1.7m
David Connolly
Head of Investor Relations & Corporate Communicationsno dataVeri yokVeri yok
Jim Flaherty
Senior VP & General Counsel5.5yrsVeri yokVeri yok
Sarah Ryan
Vice President of Sales & Marketingno dataVeri yokVeri yok
Pamela Cramer
Chief Human Resources Officer4.8yrsVeri yok0.043%
$ 2.7m
Elisabeth Cronert-Bendell
Senior VP & Head of Strategy4.3yrsVeri yokVeri yok
5.5yrs
Ortalama Görev Süresi
51.5yo
Ortalama Yaş

Deneyimli Yönetim: RYTM 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.5 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
David Meeker
Chairman10.5yrsUS$17.54m0.35%
$ 21.7m
Kimberly Popovits
Independent Directorless than a yearVeri yokVeri yok
Jennifer Good
Independent Director6.9yrsUS$659.98k0.010%
$ 634.2k
David W. McGirr
Independent Director10.5yrsUS$674.98k0.010%
$ 634.2k
Lynn Tetrault
Independent Lead Director5.4yrsUS$669.98k0.010%
$ 634.2k
Christophe Jean
Independent Director11.1yrsUS$659.98k0.010%
$ 634.2k
William Chin
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Elizabeth Stoner
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Michael Camilleri
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Lee Kaplan
Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
John Amatruda
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Stuart Arbuckle
Independent Director6.8yrsUS$659.98k0.010%
$ 634.2k
6.9yrs
Ortalama Görev Süresi
70.5yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: RYTM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 08:03
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Rhythm Pharmaceuticals, Inc. 27 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Tazeen AhmadBofA Global Research
Whitney IjemCanaccord Genuity
Samantha Lynn SemenkowCitigroup Inc